Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The German drug discovery firm Evotec has agreed to acquire Renovis, a South San Francisco biotech company focused on pain and inflammatory disease drugs. The all-stock transaction, valued at about $152 million, is expected to create a company with three clinical drug candidates and a strong preclinical pipeline. The proposed deal follows a period of divestment for Evotec. The company sold its technologies business to PerkinElmer this year and recently announced the sale of its chemical development business to Aptuit (C&EN, Sept. 17, page 17).
This article has been sent to the following recipient: